A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells

Molecular Pharmacology

Volumn 78, Issue 2, 2010, Pages 319-324

  Shah, Parag P ^a   Wang, Tianhua ^a   Kaletsky, Rachel L ^b   Myers, Michael C ^b   Purvis, Jeremy E ^a   Jing, Huiyan ^a   Huryn, Donna M ^b   Greenbaum, Doron C ^b   Smith III, Amos B ^b   Bates, Paul ^b   Diamond, Scott L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; ANTIVIRUS AGENT; CATHEPSIN B; CATHEPSIN L; CID 16725315; CID 23631927; CYSTEINE PROTEINASE INHIBITOR; DOXORUBICIN; OXOCARBAZATE; THIOCARBAZATE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AORTA; ARTICLE; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DILUTION; DRUG POTENCY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EMBRYO CELL; ENDOTHELIUM CELL; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; KIDNEY CELL; KINETICS; MOLECULAR MODEL; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ENTRY; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CATHEPSIN L; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; KINETICS; QUINOLINES; QUINOLONES; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 77954930316     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.064261     Document Type: Article

References (27)

1. Beavers MP, Myers MC, Shah PP, Purvis JE, Diamond SL, Cooperman BS, Huryn DM, and Smith AB 3rd (2008) Molecular docking of cathepsin L inhibitors in the binding site of papain. J Chem Inf Model 48:1464-1472.
2. Chandran K, Sullivan NJ, Felbor U, Whelan SP, and Cunningham JM (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645.
3. Chapman HA, Riese RJ, and Shi GP (1997) Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59:63-88.
4. Copeland RA (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. J. Wiley, Hoboken, NJ.
5. Enserink M (2003) Breakthrough of the year. SARS: a pandemic prevented. Science 302:2045.
6. Feldmann H, Jones S, Klenk HD, and Schnittler HJ (2003) Ebola virus: from discovery to vaccine. Nat Rev Immunol 3:677-685.
7. Greenbaum D, Medzihradszky KF, Burlingame A, and Bogyo M (2000) Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 7:569-581.
8. Greenbaum DC, Baruch A, Grainger M, Bozdech Z, Medzihradszky KF, Engel J, DeRisi J, Holder AA, and Bogyo M (2002) A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 298:2002-2006.
9. Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, Dermody TS, Harrison SC, Dormitzer PR, et al. (2006) SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem 281:3198-3203.
10. Hur D and Guven A (2002) The acidities of some indoles. J Mol Struct Theochem 583:1-18.
11. Kaletsky RL, Simmons G, and Bates P (2007) Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol 81:13378-13384.
12. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, and Saphire EO (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177-182.
13. Maehr R, Mintern JD, Herman AE, Lennon-Duménil AM, Mathis D, Benoist C, and Ploegh HL (2005) Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. J Clin Invest 115:2934-2943.
14. McGrath ME (1999) The lysosomal cysteine proteases. Annu Rev Biophys Biomol Struct 28:181-204.
15. Myers MC, Shah PP, Beavers MP, Napper AD, Diamond SL, Smith AB 3rd, and Huryn DM (2008a) Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype. Bioorg Med Chem Lett 18:3646-3651.
16. Myers MC, Shah PP, Diamond SL, Huryn DM, and Smith AB 3rd (2008b) Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor. Bioorg Med Chem Lett 18:210-214.
17. Pager CT and Dutch RE (2005) Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J Virol 79:12714-12720.
18. Palermo C and Joyce JA (2008) Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29:22-28.
19. Potts W, Bowyer J, Jones H, Tucker D, Freemont AJ, Millest A, Martin C, Vernon W, Neerunjun D, Slynn G, et al. (2004) Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 85:85-96.
20. Rossi A, Deveraux Q, Turk B, and Sali A (2004) Comprehensive search for cysteine cathepsins in the human genome. Biol Chem 385:363-372. (Pubitemid 38787114)
21. Schedel J, Seemayer CA, Pap T, Neidhart M, Kuchen S, Michel BA, Gay RE, Müller-Ladner U, Gay S, and Zacharias W (2004) Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther 11:1040-1047.
22. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, and White J (2006) Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80:4174-4178.
23. Shah PP, Myers MC, Beavers MP, Purvis JE, Jing H, Grieser HJ, Sharlow ER, Napper AD, Huryn DM, Cooperman BS, et al. (2008) Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L. Mol Pharmacol 74:34-41.
24. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, and Bates P (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 102:11876-11881.
25. Turk D and Guncar G (2003) Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr 59:203-213. (Pubitemid 36224841)
26. Turk V, Turk B, and Turk D (2001) Lysosomal cysteine proteases: facts and opportunities. EMBO J 20:4629-4633.
27. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, and Turk B (2007) Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13:387-403. (Pubitemid 46477760)